Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06384755
Other study ID # 645788
Secondary ID 2022_HE2_4096596
Status Recruiting
Phase N/A
First received
Last updated
Start date April 20, 2024
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source Oslo University Hospital
Contact Carmen Simonsen, PhD
Phone 0047 90988741
Email carmen.simonsen@psykologi.uio.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to evaluate the feasibility, acceptability and efficacy of a Norwegian adaptation of the group-based intervention 'Honest Open Proud' among adults with psychotic and bipolar disorders in an outpatient setting.


Description:

Because people with mental illness experience both public and personal stigma, which is related to lower levels of recovery and wellbeing, it is common to struggle with decisions regarding potential disclosure of mental health difficulties or diagnoses. There are pros and cons with both disclosure and secrecy. Disclosure can lead to social support, followed by improved mental health and reduced public stigma, but also stigmatization and social exclusion. Secrecy can prevent stigmatization but may also lead to social isolation and thus poorer mental health and increased public stigma. Therefore, people with mental illness need help to make strategic decisions about whether, and if so, to whom, when and how they wish to disclose their mental health problems. As contact with other people with mental health difficulties is crucial to anti-stigma interventions, people with mental illness could benefit from meeting peers, especially as role models. This suggests that peer facilitators could be an important feature in a program aiming to help people with mental illness handle stigma and challenges related to disclosure. The Honest Open Proud (HOP) program was developed for this purpose. Because people with psychotic and bipolar disorders experience particularly high levels of both public and personal stigma, which negatively impacts their recovery rates, they may be especially in need of the HOP program. The investigators aim to evaluate whether a Norwegian adaptation of the HOP group program, which is facilitated by peers, is feasible and acceptable for people with psychotic and bipolar disorders in an outpatient setting. Moreover, whether it helps them handle stigma and disclosure related decisions. The investigators propose a pilot randomized controlled trial, comparing an intervention group receiving a 6-week Norwegian adaptation of the HOP program to a waiting list control group. Both groups receive treatment as usual. The main research question is whether this intervention is feasible and acceptable. However, efficacy measures tapping change in stigma and disclosure distress, as well as recovery and wellbeing, from before to after the intervention, were included. The aim is to find what effect sizes can be expected in future larger studies in Norway, rather than to find significant differences in effect sizes.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 31, 2026
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosed current psychotic (F 20) or bipolar disorder (F 30) according to International Classification of Diseases 10th Revision (ICD-10) - Age 18 to 65 - Ability to provide written informed consent. - Fluent in Norwegian (needed for self-report measures) - Experience difficulties with stigma and disclosure regarding mental illness. Exclusion Criteria: - Intellectual disability - Organic disorders

Study Design


Intervention

Behavioral:
Honest Open Proud program
The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.

Locations

Country Name City State
Norway Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital Oslo
Norway Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital Oslo

Sponsors (2)

Lead Sponsor Collaborator
Oslo University Hospital University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Disclosure "Have you disclosed your mental illness the last three (or six) weeks?", YES/NO "How satisfied are you with that?", from 1 (very dissatisfied) to 7 (very satisfied) Assessed at T1 and T2 (T1= week 3 and T2 = week 6)
Other Feasibility of HOP program Recruitment rates (numbers of participants in number of weeks) and drop-out rates. Tracked during trial and evaluated after completion (T2 = week 6)
Other Acceptability of HOP program participants Semi-structured focus-group interview about acceptability with HOP program participants Assessed after T2 = week 6
Other Acceptability of HOP peer facilitators Semi-structured focus-group interview about acceptability with HOP peer facilitators Assessed after T2 = week 6
Primary Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009) 8 items, from 1 (strongly disagree) to 7 (strongly agree) Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6)
Secondary Disclosure Distress (Rüsch et al., 2014a) 1 item "In general, how distressed or worried are you in terms of secrecy or disclosure of your mental illness to others?", from 1 (not at all) to 7 (very much) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
Secondary Warwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007) 14-items, from 1 (not at all) to 5 (all the time) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
Secondary Satisfaction with life (Lehman, 1988) 1 item from Lehmans Quality of Life Scale, from 1 (very dissatisfied) to 7 (very satisfied) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
Secondary The Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007) 15 items short version, from 0 (strongly disagree) to 4 (strongly agree) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
Secondary Internalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014) 10-item short version, from 1 (strongly disagree ) to 4 (strongly agree ) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
Secondary Patient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009) 9 items, 0 (not at all) to 3 (nearly every day) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
Secondary Generalized Anxiety disorder (GAD-7) (Spitzer et al, 2006) 7 items, from 0 (not at all) to 3 (nearly every day) Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6)
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2